<DOC>
	<DOCNO>NCT01010776</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness , tolerability ( well participant stand particular medicine treatment ) , safety flexible-dose paliperidone extend release ( ER ) participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) , previously take risperidone ( antipsychotic ) , satisfied treatment .</brief_summary>
	<brief_title>A Study Evaluate Participants Satisfaction , Quality Life Effectiveness Flexible-Dose Paliperidone Extended Release ( ER ) Participants With Schizophrenia , Previously Treated With Risperidone</brief_title>
	<detailed_description>This open-label ( medical research study participant researcher tell treatment participant receive , `` unblinded '' ) , multi-center ( 1 hospital medical school team work medical research study ) , non-randomized , single-arm study paliperidone ER participants previously treat risperidone poor response . The study consist 2 phase : main phase 6 month extension phase another 6 month . The total duration study 12 month . All participant receive oral ( mouth ) daily dose paliperidone ER flexible dosage ( range 3-12 milligram [ mg ] : 3 mg , 6 mg , 9 mg , 12 mg ) accord Investigator 's discretion . Efficacy safety participant primarily evaluate Positive Negative Syndrome Scale ( PANSS ) Extrapyramidal Symptoms Rating Scale ( ESRS ) , respectively . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Female participant must postmenopausal ( time life woman stop menstrual period ) surgically sterile sexually active , practice effective method birth control ( e.g. , oral contraceptive , intrauterine device [ IUD intrauterine device make plastic and/or copper insert womb [ uterus ] way vaginal canal use prevent pregnancy ] , diaphragm spermicide [ agent kill spermatozoa ] condom [ cover worn penis sexual intercourse prevent infection pregnancy ] spermicide ) throughout study negative serum beta Human Chorionic Gonadotropin ( HCG ) pregnancy test screen Participants oral monotherapy ( treatment single drug ) risperidone regimen within daily dosage recommend package insert adhere prescribe risperidone regimen least 30 day enter study Participants partial response current risperidone regimen ( persistent symptom unstable clinical condition ) presence unbearable side effect Potential Participants switch another atypical antipsychotic due clinical response and/or side effect profile . Participants past current history psychiatric disease schizophrenia accord Diagnostic Statistical Manual Mental Disorders ( DSM ) IV Participants concomitant ( give time ) severe ( serious , life threaten ) medical neurological disorder risk suicide Participants previously use clozapine Participants history previous nonresponsiveness oral antipsychotic treatment Pregnant breastfeed female participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
</DOC>